Lack of Electrocardiographic Effects of Deucravacitinib in Healthy SubjectsAnjaneya Chimalakonda, Bindu Murthy, Shalabh Singhal et al.|Clinical Pharmacology in Drug Development|2022Cited by 12
Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy ParticipantsSébastien Bihorel, Ihab Girgis, Huadong Sun et al.|Clinical Pharmacology in Drug Development|2020Cited by 6
THU0190 THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BMS-986166, A NOVEL, SELECTIVE, PARTIAL AGONIST OF THE SPHINGOSINE-1-PHOSPHATE (S1P) SUBTYPE 1 RECEPTOR IN HEALTHY PARTICIPANTSShalabh Singhal, John Throup, Ihab Girgis et al.|Annals of the Rheumatic Diseases|2019Cited by 4
The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participantsShalabh Singhal, John Throup, Ihab Girgis et al.|Expert Opinion on Investigational Drugs|2020Cited by 4
5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY)Shalabh Singhal, Joan T. Merrill, Vaishali Shah et al.|Abstracts|2019Cited by 3